Angiogenesis Inhibitors and Hypertension: An Emerging Issue
- 20 March 2006
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (9) , 1329-1331
- https://doi.org/10.1200/jco.2005.04.5740
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Mechanisms of Hypertension Associated With BAY 43-9006Journal of Clinical Oncology, 2006
- Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid TumorsClinical Cancer Research, 2005
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsAnnals of Oncology, 2005
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseBlood, 2005
- Manipulating angiogenesis in medicineJournal of Internal Medicine, 2004
- Angiogenic growth factors and hypertensionAngiogenesis, 2004
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584Seminars in Oncology, 2003
- The VIVA TrialCirculation, 2003
- Modifications structurelles et fonctionnelles de la microcirculation dans l???hypertensionDrugs, 2003